NEW YORK (GenomeWeb News) – Sangamo BioSciences today said that it has licensed to Pfizer the use of certain zinc finger protein nuclease reagents for use in clinical and commercial production of therapeutic proteins.
 
The Richmond, Calif.-based firm said that it had licensed to Pfizer non-exclusive, worldwide rights to use the reagents to permanently eliminate the glutamine synthetase gene in Chinese Hamster Ovary cell lines. The cells will be used for producing the therapeutic proteins.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.